Denali Therapeutics (DNLI) Accumulated Depreciation & Amortization: 2017-2024
- Denali Therapeutics' Accumulated Depreciation & Amortization rose 13.13% to $52.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $164.6 million, marking a year-over-year increase of 23.42%. This contributed to the annual value of $7.8 million for FY2024, which is 53.37% down from last year.
- According to the latest figures from Q4 2024, Denali Therapeutics' Accumulated Depreciation & Amortization is $52.0 million, which was up 13.13% from $46.0 million recorded in Q4 2023.
- Over the past 5 years, Denali Therapeutics' Accumulated Depreciation & Amortization peaked at $52.0 million during Q4 2024, and registered a low of $20.8 million during Q4 2020.
- Over the past 3 years, Denali Therapeutics' median Accumulated Depreciation & Amortization value was $46.0 million (recorded in 2023), while the average stood at $45.1 million.
- Data for Denali Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY skyrocketed of 69.49% (in 2020) over the last 5 years.
- Denali Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $20.8 million in 2020, then skyrocketed by 41.06% to $29.3 million in 2021, then grew by 26.82% to $37.2 million in 2022, then grew by 23.61% to $46.0 million in 2023, then grew by 13.13% to $52.0 million in 2024.
- Its Accumulated Depreciation & Amortization was $52.0 million in Q4 2024, compared to $46.0 million in Q4 2023 and $37.2 million in Q4 2022.
